PDT Partners LLC Cuts Stock Position in Acelyrin, Inc. (NASDAQ:SLRN)

PDT Partners LLC reduced its position in Acelyrin, Inc. (NASDAQ:SLRN) by 72.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 21,860 shares of the company’s stock after selling 58,684 shares during the quarter. PDT Partners LLC’s holdings in Acelyrin were worth $69,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Wells Fargo & Company MN boosted its holdings in shares of Acelyrin by 21.9% in the fourth quarter. Wells Fargo & Company MN now owns 52,014 shares of the company’s stock valued at $163,000 after acquiring an additional 9,332 shares in the last quarter. Virtu Financial LLC acquired a new position in Acelyrin during the 3rd quarter worth approximately $50,000. XTX Topco Ltd purchased a new position in shares of Acelyrin during the 4th quarter worth approximately $33,000. Boothbay Fund Management LLC lifted its holdings in shares of Acelyrin by 54.8% in the 4th quarter. Boothbay Fund Management LLC now owns 29,828 shares of the company’s stock valued at $94,000 after buying an additional 10,554 shares during the period. Finally, Intech Investment Management LLC boosted its stake in shares of Acelyrin by 71.0% in the fourth quarter. Intech Investment Management LLC now owns 26,587 shares of the company’s stock valued at $83,000 after buying an additional 11,040 shares in the last quarter. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Citigroup reduced their target price on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. HC Wainwright reduced their price objective on shares of Acelyrin from $8.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $9.60.

Insider Buying and Selling

In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the business’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the transaction, the chief executive officer now directly owns 671,753 shares in the company, valued at approximately $1,840,603.22. The trade was a 2.61 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 13.60% of the stock is currently owned by company insiders.

Acelyrin Trading Down 0.4 %

NASDAQ:SLRN opened at $2.57 on Friday. Acelyrin, Inc. has a twelve month low of $1.85 and a twelve month high of $7.25. The company has a market capitalization of $259.33 million, a P/E ratio of -1.04 and a beta of 1.07. The firm has a 50-day moving average price of $2.47 and a two-hundred day moving average price of $3.25.

Acelyrin (NASDAQ:SLRN) last posted its earnings results on Wednesday, March 19th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.07. On average, equities research analysts predict that Acelyrin, Inc. will post -2.53 earnings per share for the current year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.